Study shows diabetes drug promising
Key points
- Denmark's Novo Nordisk, the world's biggest maker of insulin, said on Friday a phase II study showed promising results for its diabetes drug liraglutide.
- "The impressive clinical data for liraglutide holds great promise for improving the treatment of type 2 diabetes; simultaneous glucose control and weight loss in the absence of hypoglycaemic events," Novo Nordisk chief science officer Mads Krogsgaard Thomsen said in a statement.
- NovoNordisk said phase III studies with liraglutide would begin in February 2006.
Denmark's Novo Nordisk, the world's biggest maker of insulin, said on Friday a phase II study showed promising results for its diabetes drug liraglutide.
"The impressive clinical data for liraglutide holds great promise for improving the treatment of type 2 diabetes; simultaneous glucose control and weight loss in the absence of hypoglycaemic events," Novo Nordisk chief science officer Mads Krogsgaard Thomsen said in a statement.
NovoNordisk said phase III studies with liraglutide would begin in February 2006.
Written and revised by
David Cohen, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Diabetes & Hormones →
NewsStudy shows overeating impairs brain insulin function, can lead to diabetes and obesity
New research from Mount Sinai School of Medicine sheds light on how overeating can cause a malfunction in brain insulin signaling, and lead to obesity and diabetes. Christoph Buettner, MD, PhD, Associate Professor of…
18 October 2012
NewsMerck's once-a-week diabetes drug effective in clinical study
An experimental once-a-week drug for type 2 diabetes being developed by Merck & Co proved effective in lowering blood sugar levels in a mid-stage clinical trial, according to data presented on Wednesday. The pill, known…
4 October 2012
NewsCan drug coverage erase the income gap in diabetes?
Universal drug coverage might help partly close the gap between the rich and the poor when it comes to diabetes complications, a new Canadian study suggests. Researchers found that much of the income gap in heart risks…
